China Resources Pharmaceutical Group Ltd. (HK:3320) has released an update.
Dong-E-E-Jiao, a subsidiary of China Resources Pharmaceutical Group Ltd., has announced a significant increase in net profit for the first nine months of 2024, estimating a rise of 40-50% year-over-year to between RMB1.1 billion and RMB1.175 billion. This growth is attributed to their ‘growth with quality’ strategy, consumer-centric approach, and advancements in pharmaceuticals and healthcare consumer products, leading to increased brand strength and improved operational quality.
For further insights into HK:3320 stock, check out TipRanks’ Stock Analysis page.
